| Medulloblastoma genotype dictates blood brain barrier phenotype TN Phoenix, DM Patmore, S Boop, N Boulos, MO Jacus, YT Patel, ... Cancer cell 29 (4), 508-522, 2016 | 319 | 2016 |
| Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: update of the literature MO Jacus, VM Daryani, KE Harstead, YT Patel, SL Throm, CF Stewart Clinical pharmacokinetics 55, 297-311, 2016 | 53 | 2016 |
| ABCG2 transporter expression impacts group 3 medulloblastoma response to chemotherapy M Morfouace, S Cheepala, S Jackson, Y Fukuda, YT Patel, S Fatima, ... Cancer research 75 (18), 3879-3889, 2015 | 40 | 2015 |
| Ceftolozane-tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intra … KB Larson, YT Patel, S Willavize, JS Bradley, EG Rhee, L Caro, ML Rizk Antimicrobial Agents and Chemotherapy 63 (6), 10.1128/aac. 02578-18, 2019 | 30 | 2019 |
| Development and validation of LC–MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer’s solution and its application to a cerebral … A Kala, YT Patel, A Davis, CF Stewart Journal of Chromatography B 1057, 110-117, 2017 | 25 | 2017 |
| CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors YT Patel, A Davis, SJ Baker, O Campagne, CF Stewart Cancer chemotherapy and pharmacology 84, 447-452, 2019 | 22 | 2019 |
| Pharmacokinetic basis for dosing high‐dose methotrexate in infants and young children with malignant brain tumours JC Panetta, JK Roberts, J Huang, T Lin, VM Daryani, KE Harstead, ... British Journal of Clinical Pharmacology 86 (2), 362-371, 2020 | 21 | 2020 |
| Establishing a preclinical multidisciplinary board for brain tumors BV Nimmervoll, N Boulos, B Bianski, J Dapper, M DeCuypere, A Shelat, ... Clinical Cancer Research 24 (7), 1654-1666, 2018 | 19 | 2018 |
| Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data MO Jacus, SL Throm, DC Turner, YT Patel, BB Freeman III, M Morfouace, ... European journal of pharmaceutical sciences 57, 41-47, 2014 | 19 | 2014 |
| Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors M Morfouace, B Nimmervoll, N Boulos, YT Patel, A Shelat, BB Freeman, ... Journal of neuro-oncology 126, 225-234, 2016 | 18 | 2016 |
| Population pharmacokinetic analysis for plasma and epithelial lining fluid ceftolozane/tazobactam concentrations in patients with ventilated nosocomial pneumonia Z Zhang, YT Patel, J Fiedler‐Kelly, HP Feng, CJ Bruno, W Gao The Journal of Clinical Pharmacology 61 (2), 254-268, 2021 | 17 | 2021 |
| Population pharmacokinetics of selumetinib and its metabolite N‐desmethyl‐selumetinib in adult patients with advanced solid tumors and children with low‐grade gliomas YT Patel, VM Daryani, P Patel, D Zhou, J Fangusaro, DJ Carlile, ... CPT: pharmacometrics & systems pharmacology 6 (5), 305-314, 2017 | 16 | 2017 |
| CNS penetration of the CDK4/6 inhibitor ribociclib (LEE011) in non-tumor bearing mice and mice bearing orthotopic pediatric brain tumors Y Patel, A Davis, A Kala, J Roberts, M Jacus, S Baker, M Roussel, ... Neuro-Oncology 18 (6), 152, 2016 | 12 | 2016 |
| Population pharmacokinetics of vericiguat in patients with heart failure with reduced ejection fraction: an integrated analysis ME Trujillo, L Arrington, Y Patel, J Passarell, L Wenning, RO Blaustein, ... Clinical Pharmacology & Therapeutics 112 (5), 1061-1069, 2022 | 11 | 2022 |
| CNS penetration of cyclophosphamide and metabolites in mice bearing group 3 medulloblastoma and non-tumor bearing mice O Campagne, A Davis, B Zhong, S Nair, V Haberman, YT Patel, L Janke, ... Journal of Pharmacy & Pharmaceutical Sciences 22, 612-629, 2019 | 11 | 2019 |
| Danicopan as add-on therapy to ravulizumab or eculizumab versus placebo in patients with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis … A Kulasekararaj, M Griffin, CI Piatek, J Shammo, JI Nishimura, ... Blood 142, 576, 2023 | 10 | 2023 |
| Comparison of lost productivity due to eculizumab and ravulizumab treatments for paroxysmal nocturnal hemoglobinuria in France, Germany, Italy, Russia, Spain, the United … AR Levy, L Dysart, Y Patel, A Briggs, J Schneider, KJ Myren, I Tomazos Blood 134, 4803, 2019 | 10 | 2019 |
| Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study YT Patel, MO Jacus, N Boulos, JD Dapper, AD Davis, PK Vuppala, ... Cancer chemotherapy and pharmacology 75, 897-906, 2015 | 10 | 2015 |
| Translational Pharmacokinetic‐Pharmacodynamic Modeling and Simulation: Optimizing 5‐Fluorouracil Dosing in Children With Pediatric Ependymoma VM Daryani, YT Patel, M Tagen, DC Turner, AM Carcaboso, JM Atkinson, ... CPT: pharmacometrics & systems pharmacology 5 (4), 211-221, 2016 | 9 | 2016 |
| Low rate of clinically evident extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with a complement C5 inhibitor: results from a large … J Shammo, A Gajra, Y Patel, I Tomazos, J Kish, A Hill, JR Sierra, D Araten Journal of Blood Medicine, 425-437, 2022 | 8 | 2022 |
